AU2010291212A1 - Heteroaryl compounds as kinase inhibitors - Google Patents

Heteroaryl compounds as kinase inhibitors Download PDF

Info

Publication number
AU2010291212A1
AU2010291212A1 AU2010291212A AU2010291212A AU2010291212A1 AU 2010291212 A1 AU2010291212 A1 AU 2010291212A1 AU 2010291212 A AU2010291212 A AU 2010291212A AU 2010291212 A AU2010291212 A AU 2010291212A AU 2010291212 A1 AU2010291212 A1 AU 2010291212A1
Authority
AU
Australia
Prior art keywords
alkyl
haloalkyl
branched
hydrogen
cyclo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2010291212A
Other languages
English (en)
Inventor
Keith B. Pfister
Martin Sendzik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2010291212A1 publication Critical patent/AU2010291212A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2010291212A 2009-09-04 2010-09-02 Heteroaryl compounds as kinase inhibitors Abandoned AU2010291212A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27593909P 2009-09-04 2009-09-04
US61/275,939 2009-09-04
PCT/EP2010/062908 WO2011026917A1 (en) 2009-09-04 2010-09-02 Heteroaryl compounds as kinase inhibitors

Publications (1)

Publication Number Publication Date
AU2010291212A1 true AU2010291212A1 (en) 2012-02-23

Family

ID=43532948

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010291212A Abandoned AU2010291212A1 (en) 2009-09-04 2010-09-02 Heteroaryl compounds as kinase inhibitors

Country Status (9)

Country Link
US (1) US20120157433A1 (ko)
EP (1) EP2473502A1 (ko)
KR (1) KR20120049940A (ko)
CN (1) CN102498107A (ko)
AU (1) AU2010291212A1 (ko)
BR (1) BR112012008147A2 (ko)
CA (1) CA2771568A1 (ko)
MX (1) MX2012002752A (ko)
WO (1) WO2011026917A1 (ko)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ627520A (en) * 2010-03-10 2015-10-30 Astrazeneca Ab 4-phenyl pyridine analogues as protein kinase inhibitors
WO2012066065A1 (en) * 2010-11-17 2012-05-24 Novartis Ag Phenyl-heteroaryl amine compounds and their uses
WO2012101064A1 (en) * 2011-01-28 2012-08-02 Novartis Ag N-acyl pyrimidine biaryl compounds as protein kinase inhibitors
CN103917527B (zh) 2011-09-16 2017-05-31 拜耳知识产权有限责任公司 二取代的5‑氟‑嘧啶
CA2888381A1 (en) 2012-10-18 2014-04-24 Bayer Pharma Aktiengesellschaft 4-(ortho)-fluorophenyl-5-fluoropyrimidin-2-yl amines containing a sulfone group
CA2888371C (en) 2012-10-18 2021-06-08 Ulrich Lucking 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfone group
TW201418243A (zh) 2012-11-15 2014-05-16 Bayer Pharma AG 含有磺醯亞胺基團之ｎ－（吡啶－２－基）嘧啶－４－胺衍生物
CN105764887A (zh) 2013-09-12 2016-07-13 住友化学株式会社 含氮饱和杂环化合物
CA2964683A1 (en) 2014-10-16 2016-04-21 Bayer Pharma Aktiengesellschaft Fluorinated benzofuranyl-pyrimidine derivatives containing a sulfone group
ES2728356T3 (es) * 2015-06-29 2019-10-23 Astrazeneca Ab Derivados de amidas policíclicas como inhibidores de CDK9
US10717749B2 (en) 2015-09-29 2020-07-21 Bayer Pharma Aktiengesellschaft Macrocyclic sulfondiimine compounds
JP6888000B2 (ja) 2015-10-08 2021-06-16 バイエル ファーマ アクチエンゲゼルシャフト 新規な修飾された大環状化合物
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
US11242356B2 (en) 2017-03-28 2022-02-08 Bayer Aktiengesellschaft PTEFb inhibiting macrocyclic compounds
ES2900199T3 (es) 2017-03-28 2022-03-16 Bayer Ag Novedosos compuestos macrocíclicos inhibidores de PTEFB
EA202091894A1 (ru) 2018-02-13 2020-12-28 Байер Акциенгезельшафт Применение 5-фтор-4-(4-фтор-2-метоксифенил)-n-{4-[(s-метилсульфонимидоил)метил]пиридин-2-ил}пиридин-2-амина для лечения диффузной в-крупноклеточной лимфомы
CN112574181A (zh) * 2019-09-30 2021-03-30 天津药业研究院股份有限公司 苏沃雷生中间体的制备方法及应用
CA3179627A1 (en) * 2020-05-27 2021-12-02 Aaron Coffin Substituted benzamides as modulators of trex1
TW202220992A (zh) 2020-08-05 2022-06-01 匈牙利商羅特格登公司 具藥理活性之經雜環取代的吡唑并〔１，５－ａ〕嘧啶衍生物
WO2022247785A1 (zh) * 2021-05-24 2022-12-01 石药集团中奇制药技术（石家庄）有限公司 一种周期蛋白依赖性激酶9抑制剂的用途
WO2022247796A1 (zh) * 2021-05-24 2022-12-01 石药集团中奇制药技术（石家庄）有限公司 周期蛋白依赖性激酶9抑制剂的用途
WO2022257965A1 (zh) * 2021-06-09 2022-12-15 石药集团中奇制药技术（石家庄）有限公司 固体形式的周期蛋白依赖性激酶9抑制剂及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
JPH0784462B2 (ja) * 1986-07-25 1995-09-13 日清製粉株式会社 ベンゾイミダゾ−ル誘導体
US20020052370A1 (en) * 2000-07-06 2002-05-02 Barber Christopher Gordon Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase
AR036053A1 (es) * 2001-06-15 2004-08-04 Versicor Inc Compuestos de n-formil-hidroxilamina, un proceso para su preparacion y composiciones farmaceuticas
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
SE0301963D0 (sv) * 2003-07-02 2003-07-02 Astrazeneca Ab New compounds
WO2007018319A1 (ja) * 2005-08-11 2007-02-15 Takeda Pharmaceutical Company Limited ピリジルフェノール化合物およびその用途
AU2008268463B2 (en) * 2007-06-22 2015-03-05 Eli Lilly And Company Methods and compositions for treating disorders

Also Published As

Publication number Publication date
KR20120049940A (ko) 2012-05-17
EP2473502A1 (en) 2012-07-11
CN102498107A (zh) 2012-06-13
BR112012008147A2 (pt) 2016-03-01
WO2011026917A1 (en) 2011-03-10
CA2771568A1 (en) 2011-03-10
US20120157433A1 (en) 2012-06-21
MX2012002752A (es) 2012-04-19

Similar Documents

Publication Publication Date Title
AU2010291212A1 (en) Heteroaryl compounds as kinase inhibitors
WO2012101063A1 (en) N-acyl pyridine biaryl compounds and their uses
AU2010277588B2 (en) Pyridine and pyrazine derivatives as protein kinase modulators
AU2010291199A1 (en) Pyrazinylpyridines useful for the treatment of proliferative diseases
WO2012101064A1 (en) N-acyl pyrimidine biaryl compounds as protein kinase inhibitors
US20110130380A1 (en) Heteroaryl Kinase Inhibitors
JP6626449B2 (ja) ＰＤＥ２阻害剤としての置換［１，２，４］トリアゾロ［１，５−ａ］ピリミジン−７−イル化合物
JP5746972B2 (ja) ホスホジエステラーゼ１０阻害剤としてのピラジン化合物
RU2332412C2 (ru) Производные пиразола
RU2425826C2 (ru) СОЕДИНЕНИЯ И КОМПОЗИЦИИ В КАЧЕСТВЕ ИНГИБИТОРОВ ITPKb
KR101921404B1 (ko) 신규 2치환 1,2,4-트리아진 화합물
KR20210040368A (ko) 사이클린 의존성 키나제의 억제제
MX2013000575A (es) Compuestos heterociclicos activadores de proteina cinasa activada por 5'-amp (ampk) y metodos para emplearlos.
WO2005082855A1 (ja) 新規ピリジン誘導体およびピリミジン誘導体（２）
WO2012066070A1 (en) 3-(aminoaryl)-pyridine compounds
EA013250B1 (ru) Ингибиторы c-fms киназы
JP2009542638A (ja) グリコーゲン・シンターゼ・キナーゼ（ｇｓｋ３）に関連する疾患の治療のためのイミダゾール−ピリミジン誘導体
WO2012101066A1 (en) Pyridine biaryl amine compounds and their uses
MX2011006575A (es) Compuestos de aminopiridina y carboxipiridina como inhibidores de la fosfodiesterasa 10.
WO2012101065A2 (en) Pyrimidine biaryl amine compounds and their uses
AU2011253058A1 (en) Heteroaryloxycarbocyclyl compounds as PDE10 inhibitors
KR20190133199A (ko) 브루톤 타이로신 키나제 억제제
KR20240005838A (ko) 포스포닐 유도체 및 이의 조성물과 약학적 응용
JP2023545065A (ja) オートタキシン抑制剤化合物
EP4141003A1 (en) Pyrazolo[1,5-a]pyridine derivative, preparation method therefor, and composition and use thereof

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted